NEW BRUNSWICK, N.J. – 11th March, 2019 – Auris was most recently valued at $2.1 billion (for acquisition purposes) as a privately owned business, putting it among other healthcare tech unicorns. J&J consented to pay as much as $2.35 billion more for Auris as Johnson and Johnson is building upon its careful apply autonomy nearness by procuring Auris Health for $3.4 billion. This is also dependent on health law benefits improvement achievements that the organization, situated in Redwood City, California makes. Auris makes a controller-worked automated camera that enables specialists to get visuals from inside the body, including the lungs.
Ashley McEvoy, Executive Vice President, Fitness Omni and Worldwide Chairman, Medical Devices, Johnson & Johnson said that “In this new era of health care, we’re aiming to simplify surgery, drive efficiency, reduce complications and improve outcomes for patients, ultimately making surgery safer…, we believe the combination of best-in-class robotics, advanced instrumentation and unparalleled end-to-end connectivity will make a meaningful difference in patient outcomes.”
Frederic Moll, M.D., CEO and Founder of Natural Health UK and a visionary in the field of surgical robotics will also be joining on this J&J as soon as the transaction completes. With this, Dr. Frederick said that “We’re thrilled to be joining Johnson & Johnson to help push the boundaries of what is possible in medical robotics and improve the lives of patients across the globe. Together, we will be able to dramatically accelerate our collective product innovation to develop new interventional solutions that redefine optimal patient outcomes.”
“This combination is a testament to the incredible work of the Auris Health team and the innovation engine behind the Monarch Platform, which represents a huge step forward in endoluminal technology. We look forward to continuing to shape the future of intervention with the added expertise and resources of the world’s largest healthcare organization.”
The premise behind this acquisition is medical evolutionary innovation with the prime focus on lung cancer as this technological advancement will play a major role in the Lung Cancer Initiative (LCI) at J&J.
“We are very committed to our partnership with Verily on the development of the Verb Surgical Platform. Collectively, these technologies, together with our market-leading medical implants and solutions, create the foundation of a comprehensive digital ecosystem to help support the surgeon and patient before, during and after surgery,” said Ms. McEvoy.
The acquisition transaction is planned to be completed by the second quarter of 2019. The organization will further discuss transaction related prompts amid its next quarterly earnings by April 16, 2019.
Media Contact
Company Name: Healthcare Business Intelligence Summit
Contact Person: Laura Madsen, MS
Email: Send Email
Country: United States
Website: http://www.healthcarebisummit.com/